BIOMAT Database Logo BIOMAT Database Logo

Epileptics on phenytoin. 1970

F J Vajda, and R J Prineas

UI MeSH Term Description Entries
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

F J Vajda, and R J Prineas
SERUM PHENYTOIN DETERMINATIONS IN EPILEPTICS.
December 1964, Epilepsia,
F J Vajda, and R J Prineas
Salivary phenytoin levels in institutionalized epileptics.
January 1983, Journal of chronic diseases,
F J Vajda, and R J Prineas
Phenytoin kinetics in Japanese adult epileptics: phenotype of phenytoin slow metabolizers.
August 1997, Clinical neuropharmacology,
F J Vajda, and R J Prineas
Phenytoin induced gingival overgrowth in institutionalized epileptics.
April 1984, Journal of clinical periodontology,
F J Vajda, and R J Prineas
Age and phenytoin kinetics in adult epileptics.
March 1982, Clinical pharmacology and therapeutics,
F J Vajda, and R J Prineas
Cerebellar atrophy in phenytoin-treated mentally retarded epileptics.
September 1977, Epilepsia,
F J Vajda, and R J Prineas
Long-term use of phenytoin: effect on haematological parameters in Nigerian epileptics.
February 1988, The Central African journal of medicine,
F J Vajda, and R J Prineas
Therapeutic plasma concentration in epileptics treated with phenytoin alone.
January 1980, Folia psychiatrica et neurologica japonica,
F J Vajda, and R J Prineas
[Plasma concentration of phenytoin in epileptics--importance for the clinician].
July 1975, Schweizerische medizinische Wochenschrift,
F J Vajda, and R J Prineas
Cerebrospinal fluid and blood thiamine concentrations in phenytoin-treated epileptics.
February 1982, The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques,
Copied contents to your clipboard!